Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
NCT02248987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36
Last updated 2019-04-08
Summary
The purpose of this study is to evaluate abnormal dopamine synthesis and connectivity according to the antipsychotic treatment response in schizophrenia.
Conditions
Interventions
- OTHER
-
patients treated with antipsychotics
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-05-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
Countries
- South Korea
Study Locations
More Related Trials
-
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
NCT03649581 ·Status: RECRUITING ·Phase: NA
-
Oculomotor and Spatial Cognition Deficits in Schizophrenia
NCT00931996 ·Status: TERMINATED ·Phase: NA
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia
NCT01545999 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions
NCT00155519 ·Status: COMPLETED
-
Prevalence of Metabolic Syndrome in Patients With Schizophrenia in Korea
NCT01477918 ·Status: UNKNOWN
-
The Effect of Paliperidone Palmitate in Schizophrenia
NCT01860781 ·Status: COMPLETED ·Phase: PHASE4
-
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia
NCT06574360 ·Status: RECRUITING ·Phase: PHASE2
-
Social Dysfunction and Brain Dysfunction in Patients With Schizophrenia
NCT01903915 ·Status: UNKNOWN
-
Prevalence of the Metabolic Syndrome in SPR Taking Antipsychotics
NCT00569504 ·Status: UNKNOWN
-
Quetiapine Related Neurochemical Changes as Measured by Magnetic Resonance Spectroscopy in Schizophrenia
NCT00797927 ·Status: COMPLETED ·Phase: PHASE4
-
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197 ·Status: RECRUITING ·Phase: PHASE2
-
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
NCT04959201 ·Status: RECRUITING ·Phase: PHASE2
-
Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
NCT02868879 ·Status: COMPLETED
-
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia
NCT01943175 ·Status: COMPLETED
-
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297 ·Status: COMPLETED ·Phase: PHASE2
-
Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
NCT03284294 ·Status: UNKNOWN ·Phase: PHASE3
-
Sustained Attention Abilities in Schizophrenia
NCT02388607 ·Status: UNKNOWN
-
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
NCT01016145 ·Status: UNKNOWN ·Phase: PHASE4
-
Predicting Antipsychotic Discontinuation in Psychosis
NCT02884518 ·Status: UNKNOWN ·Phase: NA
-
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
NCT00482430 ·Status: COMPLETED ·Phase: PHASE2
-
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
NCT03019887 ·Status: COMPLETED ·Phase: NA
-
A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
NCT01490567 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
NCT01339858 ·Status: COMPLETED ·Phase: PHASE4
-
Exploring the Effectiveness of Group Cognitive Stimulation Therapy in People With Schizophrenia.
NCT04916483 ·Status: UNKNOWN ·Phase: NA